Skip to main content
. 2022 Jan 10;56(2):212–219. doi: 10.1007/s43441-021-00371-z

Table 2.

Comparison of Applications Reviewed Under RTOR and RTOR Combined with Project Orbis Since the Launch of Project Orbis in 2019 to May 2021

Total Applications Median Approval Time (Range) Mean Approval Time
RTOR and Project ORBIS 21 (5 NMEs)a 4.5 Months (1.5, 8) 4.4 Months
RTOR Alone 10 (4 NMEs) 5 Months (3, 16) 6.5 Monthsb

aAll received priority review except for nivolumab sBLA

b5.4 months if dostarlimab is removed from the calculation